Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 107 3 Supplemental material Supplemental figures Figure S1. Flow chart of sample numbers and exclusion criteria per biomarker. In 27 samples none of the biomarkers were assessed. The right grey boxes indicate the exclusion criteria per biomarker and the right light grey boxes indicate the total number of samples that were assessed per biomarker. The remaining samples with ≥2 biomarker values were randomized in a training (n=55) and validation cohort (n=80). The blue boxes indicate the number of samples that were assessed per biomarker in the training (T) and validation (V) cohort.
RkJQdWJsaXNoZXIy MTk4NDMw